New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:08 EDTIDXX, DGX, EXAS, ABAX, QDEL, VIVOLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
News For IDXX;DGX;EXAS;ABAX;QDEL;VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 23, 2014
07:13 EDTDGXQuest Diagnostics narrows FY14 adjusted EPS view to $4.03-$4.07 from $4.00-$4.10
Consensus for FY14 EPS is $4.05. Narrows FY14 revenue growth view to 3.5% from 2.5%-3.5%.
07:12 EDTDGXQuest Diagnostics reports Q3 adjusted EPS $1.10, consensus $1.08
Reports Q3 revenue $1.9B, consensus $1.87B.
October 22, 2014
15:37 EDTDGXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
08:05 EDTEXASMDVIP announces Cologuard to be availble by perscription
Subscribe for More Information
07:39 EDTQDELQuidel price target raised to $30 from $27 at Canaccord
Subscribe for More Information
05:44 EDTQDELQuidel price target raised to $31 from $27 at Piper Jaffray
Subscribe for More Information
October 21, 2014
16:19 EDTQDELQuidel reports Q3 EPS (1c), consensus (12c)
Subscribe for More Information
16:05 EDTABAXAbaxis reports Q2 EPS 24c, consensus 23c
Reports Q2 revenue $53.9M, consensus $50.55M.
10:53 EDTEXASExact Sciences, Lumber Liquidators shorts recomended by Tilson, Bloomberg says
Kase Capital's Whitney Tilson recommended short positions in Exact Sciences (EXAS) and Lumber Liquidators (LL) while speaking at the Robin Hood Conference, according to Bloomberg.
07:02 EDTABAXHenry Schein to sell Abaxis veterinary products
Subscribe for More Information
October 16, 2014
15:10 EDTDGXAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
11:21 EDTEXASOptions with decreasing implied volatility: EXAS ATLS LOCO MAT
Subscribe for More Information
07:02 EDTEXASExact Sciences CEO Conroy to be interviewed
CEO Conroy discusses the development of Cologuard, the first and only FDA approved, noninvasive stool DNA screening test for colorectal cancer in an interview on The Traders Network to be held on October 16 at 7:30 am. Webcast Link
October 15, 2014
14:01 EDTQDELQuidel receives FDA clearance for Lyra molecular PCR assay
Subscribe for More Information
11:27 EDTEXASOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INO ATLS LOCO OPK INFY EUO FDO
October 14, 2014
11:17 EDTEXASOptions with decreasing implied volatility
Subscribe for More Information
October 13, 2014
14:01 EDTQDELQuidel receives FDA clearance for Lyra molecular PCR assay
Quidel announced that it has received 510k clearance from the FDA to market its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus viral DNA isolated from nasal swab and nasopharyngeal swab specimens. Adenovirus outbreaks can occur throughout the year, but are more common from late winter to early summer. Quidel's Lyra Adenovirus Assay is part of the new Lyra brand of ready-to-use, molecular PCR reagent kits specifically designed to be compatible with a laboratory's existing thermocycler.
12:01 EDTEXASOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
10:59 EDTQDELEbola in U.S. could boost flu testing, says Piper Jaffray
Piper Jaffray believes the emergence of Ebola cases in the U.S. could drive incremental flu testing since the disease shares some initial symptoms with flu, likely driving people to get a test. Piper says it has increased confidence in its flu upside scenario for Quidel. It has an Overweight rating on the stock.
07:31 EDTEXASExact Sciences price target raised to $42 from $25 at Benchmark Co.
Benchmark Co. raised its price target for Exact Sciences shares to $42 citing the Medicare coverage decision and reimbursement rate of $502 for the company's test. The firm had previously modeled a price of $300 for Cologuard. It reiterates a Buy rating on the name.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use